sodium-morrhuate has been researched along with Obesity--Morbid* in 3 studies
3 other study(ies) available for sodium-morrhuate and Obesity--Morbid
Article | Year |
---|---|
Endoscopic sclerotherapy for the treatment of weight regain after Roux-en-Y gastric bypass: outcomes, complications, and predictors of response in 575 procedures.
Weight regain after Roux-en-Y gastric bypass (RYGB) is common. Endoscopic sclerotherapy is increasingly used to treat this weight regain.. To report safety, outcomes, durability, and predictors of response to sclerotherapy in a large prospective cohort.. Retrospective analysis of a prospective cohort study of patients with weight regain after RYGB.. A total of 231 consecutive patients undergoing 575 sclerotherapy procedures between September 2008 and March 2011.. Single or multiple sclerotherapy procedures to inject sodium morrhuate into the rim of the gastrojejunal anastomosis.. We report weight loss, complications, and predictors of response. We also used Kaplan-Meier survival analysis and log-rank test to compare time to continuation of weight regain after sclerotherapy in patients undergoing a single versus multiple sclerotherapy procedures.. At 6 and 12 months from the last sclerotherapy procedure, weight regain stabilized in 92% and 78% of the cohort, respectively. Those who underwent 2 or 3 sclerotherapy sessions had significantly higher rates of weight regain stabilization than those who underwent a single session (90% vs 60% at 12 months; P = .003). The average weight loss at 6 months from the last sclerotherapy session for the entire cohort was 10 lb (standard deviation 16), representing 18% of the weight regained after RYGB. A subset of 73 patients (32% of the cohort) had greater weight loss at 6 months (26 lb, standard deviation 12), representing 61% of the weight regained. Predictors of a favorable outcome included greater weight regain and the number of sclerotherapy procedures. Bleeding was reported in 2.4% of procedures and transient diastolic blood pressure increases in 15%, without adverse health outcomes. No GI perforations were reported.. Endoscopic sclerotherapy appears to be a safe and effective tool for the management of weight regain after RYGB. Topics: Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gastric Bypass; Gastroscopy; Humans; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Multivariate Analysis; Obesity, Morbid; Retrospective Studies; Sclerosing Solutions; Sclerotherapy; Sodium Morrhuate; Time Factors; Treatment Failure; Treatment Outcome; Weight Gain; Weight Loss | 2012 |
Weight gain after bariatric surgery as a result of a large gastric stoma: endotherapy with sodium morrhuate may prevent the need for surgical revision.
Obesity affects more than 30% of the U.S. population and is associated with the development of life-threatening complications. Numerous therapeutic approaches to the problem have been advocated, including low-calorie diets, anoretic drugs, behavior modifications, and exercise therapy. The only treatment proven to be effective in the long-term management of morbid obesity is surgical intervention. Complications of bariatric surgery include stomal stenosis and/or ulcer and stomal dilation (secondary to overeating). The latter complication can result in a gain of previously lost weight.. To determine the effect of endoscopic injection by using a sclerosant (sodium morrhuate) to induce stomal stenosis in patients who present with stomal dilatation complicated by weight gain.. Bariatric patients with a large gastric stoma were treated with sodium morrhuate stomal injection. Diameters of the stoma were followed at repeat endoscopy. Weight loss at scheduled clinic visits were compared with pretherapy weights.. Twenty-eight patients (10 men, 18 women; age range, 27-58 years), after bariatric surgery with GI bypass, were referred with weight gain after initial weight loss. Weight gain was believed to be the result of a large gastric stoma.. Treatment included injection of sodium morrhuate (1-2 mL circumferentially) surrounding the stoma. A total of 1 to 3 injection sessions were performed in an attempt to achieve a stoma diameter of 1.2 cm or smaller.. Treatment success was defined as a decrease of stoma size to Topics: Adult; Dilatation, Pathologic; Endoscopy, Gastrointestinal; Female; Gastric Bypass; Humans; Injections; Male; Middle Aged; Obesity, Morbid; Reoperation; Sclerosing Solutions; Sodium Morrhuate; Surgical Stomas; Weight Gain | 2007 |
Weight gain after bariatric surgery as a result of large gastric stoma: endotherapy with sodium morrhuate to induce stomal stenosis may prevent the need for surgical revision.
Topics: Dilatation, Pathologic; Endoscopy, Gastrointestinal; Gastric Bypass; Humans; Injections; Obesity, Morbid; Reoperation; Sclerosing Solutions; Sodium Morrhuate; Surgical Stomas; Weight Gain | 2007 |